What's the price of a hepatitis C cure?

August 4, 2016 by Greg Dore And Marianne Martinello, The Conversation
At over $1,300 a pill, a cure for hepatitis C comes at a high price. Credit: www.shutterstock.com.au

Sofosbuvir is one of a number of new direct-acting antiviral drugs revolutionising the care of people living with hepatitis C. Combinations of two or three hepatitis C virus direct-acting antiviral drugs taken for 8-24 weeks can cure more than 90% of people treated. However, this breakthrough in clinical medicine comes at a cost.

Globally, it is estimated more than 80 million people are infected with hepatitis C. Each year, 700,000 die from complications of the disease. In Australia, an estimated 230,000 people are living with C.

Complications of hepatitis C include cirrhosis, liver failure and liver cancer. Ensuring broad access to these ground-breaking therapies, including sofosbuvir, is vital to reduce liver deaths and prevent new infections.

How does it work?

The direct-acting work by blocking the action of specific proteins or enzymes in the hepatitis C virus, which are essential for the virus to replicate and infect liver cells. Sofosbuvir blocks the action of an enzyme called "NS5B RNA-dependent RNA polymerase".

While some direct-acting antiviral drugs work only on specific types or strains of hepatitis C virus, sofosbuvir is active against all six major strains of hepatitis C. Sofosbuvir has a of other features that make it ideal for widespread use in the quest for hepatitis C elimination. These include once-daily oral dosing, no need to take with food and very few side effects.

In a major therapeutic advance, on June 28, 2016, the US Food and Drug Administration (FDA) approved a combination of sofosbuvir with another direct-acting antiviral velpatasvir (Epclusa). Velpatasvir acts by blocking a different protein, the "NS5A" enzyme. Regardless of hepatitis C strain, this "one pill, once a day" treatment for 12 weeks has the potential to cure more than 95% of people infected with hepatitis C, including people with cirrhosis.

Credit: The Conversation

Sofosbuvir is very well tolerated. The most common side effects seen with the combination sofosbuvir/ledipasvir (another direct-acting antiviral that blocks the "NS5A" enzyme) are fatigue and headache.


Sofosbuvir was approved for treatment of chronic hepatitis C (as one part of combination therapy) by the US FDA in December 2013 and the Australian Therapeutic Goods Administration in August 2014.

In 2016, Australia provided broad, government-subsidised access to these new treatments for all people living with chronic hepatitis C. The initial enthusiasm for the treatment has been astounding. An estimated 22,470 Australians started hepatitis C treatment between March and June 2016.

In an effort to expand access to treatment in Australia, hepatitis C virus direct-acting antivirals can be prescribed by both specialists (gastroenterologists, hepatologists or infectious diseases physicians) and general practitioners, and can be dispensed by both community and hospital pharmacies.


Pharmaceutical company Gilead launched sofosbuvir on December 6, 2013, for the wholesale cost of US$1,000 (A$1,317) per 400mg tablet. The cost for the sofosbuvir component of a 12-week treatment course is US$84,000 (with the total cost of treatment dependent on the other medication or medications used in combination with sofosbuvir).

Although expensive, these new treatments will be cost-effective in the long term with the ability to prevent both liver-related deaths and new hepatitis C infections. from . Credit: www.shutterstock.com

In 2014, sofosbuvir generated US$10.3 billion in sales. While the high cost of treatment has come under scrutiny, Gilead's executives said "price is the wrong discussion … value should be the subject". Drug companies appear well aware such innovative treatments for hepatitis C will be well sought after regardless of cost.

With time and industry competition, drug costs have fallen marginally. Sofosbuvir combined with ledipasvir is US$94,500 (A$124,000) and the recently launched sofosbuvir combined with velpatasvir is US$64,700 (A$85,000) for a 12-week course.

In Australia, sofosbuvir is available through the Pharmaceutical Benefits Scheme for A$38.30 a month, or A$6.20 if you have a concession card.


The high cost of sofosbuvir has been a major barrier to widespread use and treatment of people with chronic hepatitis C infection, even in high-income countries. The high cost has given rise to community dissent with lobbying from large international organisations, including Medecins San Frontieres and the Joint United Nations Program on HIV/AIDS (UNAIDS), to secure access for low- and middle-income countries.

Gilead has entered into licensing deals with several manufacturers in India to provide generic to more than 100 low- and middle-income countries. However, these generic deals exclude a number of middle-income countries with very high hepatitis C burdens, leaving millions of people without access to this drug.

Facilitating global access to safe, effective direct-acting antivirals will herald a revolution in hepatitis C management. Elimination of hepatitis C as a major global public health issue is possible, if we have the political and financial will to expand access to this therapy to all populations with hepatitis C.

Although expensive, these new treatments will be cost-effective in the long term with the ability to prevent both liver-related deaths and new hepatitis C infections. Central to unlocking the public health potential of sofobuvir and other hepatitis C direct-acting antiviral drugs is liberal access to C care and .

Explore further: New study challenges the concept of treatment failure in hepatitis C

Related Stories

New study challenges the concept of treatment failure in hepatitis C

April 16, 2016
Data presented today demonstrate that choosing a different combination of direct-acting antiviral (DAA) treatment for Hepatitis C can eradicate the virus at four weeks in patients who had already failed on previous medication ...

Study demonstrates the potential for a new triple combination treatment for hepatitis C patients

April 14, 2016
A new combination treatment for hepatitis C has potential for patients who were not cured by current treatment options.

Low-cost generic direct-acting antiviral treatment for hep C is equivalent to branded formulations

April 16, 2016
Data presented today demonstrates that generic direct-acting antivirals (DAAs) are as effective and safe as branded treatments to cure Hepatitis C.

Scientists find a way to cure hepatitis C with 6 weeks of treatment

April 16, 2016
A pilot study presented today found that all patients with acute HCV who were treated with a direct-acting antiviral treatment over a 'short-duration' of six weeks had undetectable HCV after a 12 week follow-up. The investigator-initiated ...

Ledipasvir-sofosbuvir combination proves effective in subset of patients with chronic hepatitis C

April 24, 2015
A new study presented today at The International Liver Congress 2015 has demonstrated that ledipasvir (LDV) in combination with sofosbuvir (SOF) achieves sustained virologic response rates 12 weeks after treatment (SVR12; ...

Sofosbuvir tied to rare cases of bradyarrhythmia

November 5, 2015
(HealthDay)—One of the new, highly effective drugs for treating hepatitis C can cause bradyarrhythmia in some patients, according to a research letter published in the Nov. 5 issue of the New England Journal of Medicine.

Recommended for you

Discovery opens door for synthetic opioids with less addictive qualities

June 1, 2018
Making opioids from sugar instead of from field grown opium poppies has the potential to solve many of the problems associated with manufacturing strong pain killers.

US doctors prescribing fewer opioid painkillers: report

May 31, 2018
US doctors reduced the number of prescriptions for opioid painkillers last year, continuing a five-year trend, in an effort to reverse a deadly drug abuse epidemic, a report released Thursday said.

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.